1. Bi-DTPA as a high-performance CT contrast agent for in vivo imaging
- Author
-
Jinbin Pan, Xuejun Zhang, Chunshui Yu, Cai Zhang, Shao-Kai Sun, Xianting Sun, Weihua Liao, and Peng Lei
- Subjects
Materials science ,Biocompatibility ,media_common.quotation_subject ,Biophysics ,Contrast Media ,Bioengineering ,02 engineering and technology ,Biomaterials ,Mice ,03 medical and health sciences ,In vivo ,Cell Line, Tumor ,Spectroscopy, Fourier Transform Infrared ,Animals ,Contrast (vision) ,030304 developmental biology ,media_common ,0303 health sciences ,3T3 Cells ,Pentetic Acid ,021001 nanoscience & nanotechnology ,Kidney imaging ,Gastrointestinal Tract ,Solubility ,Mechanics of Materials ,Ceramics and Composites ,Female ,Tomography ,Ct imaging ,Reactive Oxygen Species ,Tomography, X-Ray Computed ,0210 nano-technology ,Preclinical imaging ,Biomedical engineering - Abstract
Clinically used iodinated computer tomography (CT) contrast agents suffer from low sensitivity, and the emerging lanthanide-chelates and CT imaging nanoagents raise great safety concerns. The fusion of high sensitivity and good biocompatibility is highly desired for the development of CT contrast agents. Herein, we propose a facile and green one-pot synthesis strategy for the fabrication of a small molecular CT contrast agent, Bi-diethylene triamine pentaacetate acid (DTPA) complex, for high-performance CT and spectral CT imaging. The Bi-DTPA exhibits yield of near 100%, outstanding water solubility, favorable biocompatibility, large-scale production capability, and superior X-ray attenuation ability, and is successfully applied in high-quality in vivo kidney imaging and gastrointestinal tract CT imaging and appealing spectral CT imaging. The proposed contrast agent can be rapidly excreted from body, avoiding the potential side effects caused by the long-term retention in vivo. Furthermore, our design shows great potential in developing diverse multifunctional contrast agents via chemical modification. The proposed Bi-DTPA with unique superiorities shows a bright prospect in clinic CT imaging, especially spectral CT imaging, and lays down a new way for the design of high-performance CT contrast agents with great clinical transformation potential.
- Published
- 2019